| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/24/2006 | CA2567468A1 Carboranylporphyrins and uses thereof |
| 08/23/2006 | EP1693456A1 Gene encoding g protein-coupled receptor and gene product thereof |
| 08/23/2006 | EP1693451A1 Method of growing myocardial cells |
| 08/23/2006 | EP1693384A2 Functional immunoglobulins against human serum albumin, fragments thereof, library thereof and methods of production thereof |
| 08/23/2006 | EP1693376A2 Crystalline composites comprising phytosterols and phytostanols or derivatives thereof |
| 08/23/2006 | EP1693374A1 Microcrystal and medicinal preparation containing the same |
| 08/23/2006 | EP1693373A1 Enantiomerically pure beta-D-(-)-dioxolane-nucleosides |
| 08/23/2006 | EP1693372A1 Novel Sulfamides and their use as endothelin receptor antagonists |
| 08/23/2006 | EP1693369A1 Protein modifier production inhibitor |
| 08/23/2006 | EP1693368A1 Process for the preparation of montelukast |
| 08/23/2006 | EP1693367A1 Piperidine compound and method for producing same |
| 08/23/2006 | EP1693365A1 Inhibitors of dipeptidyl peptidase IV |
| 08/23/2006 | EP1693360A1 Huvastatin and its preparation and formulation comprising the huvastatin |
| 08/23/2006 | EP1693067A1 Pharmaceutical anti-herpetic composition, method for producing a dosage form based thereon and method for the use thereof |
| 08/23/2006 | EP1693062A2 Androgen receptor-dependent gene expression control |
| 08/23/2006 | EP1693061A1 Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases |
| 08/23/2006 | EP1693060A1 Therapeutic or preventive agents for ischemic neuropathy |
| 08/23/2006 | EP1693059A1 Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases |
| 08/23/2006 | EP1693058A1 Prevention and measures for viral infection |
| 08/23/2006 | EP1693053A2 Steroid solution aerosol products with enhanced chemical stability |
| 08/23/2006 | EP1693052A1 Compositions for delivery of drug combinations |
| 08/23/2006 | EP1692951A1 Topical antifungal composition |
| 08/23/2006 | EP1692636A2 Methods, program products and systems for single and multi-agent dosing |
| 08/23/2006 | EP1692516A1 Method of therapy |
| 08/23/2006 | EP1692444A2 Process for co-spray drying agents with dry silicified mcc |
| 08/23/2006 | EP1692305A1 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 08/23/2006 | EP1692267A2 Methods of organ regeneration |
| 08/23/2006 | EP1692250A1 Adhesion inhibition of micro organisms by non-ionic surfactants |
| 08/23/2006 | EP1692206A1 Method of preparing carboxylic acid functionalized polymers |
| 08/23/2006 | EP1692187A1 Ec sod and cell transducing ec sod and use thereof |
| 08/23/2006 | EP1692166A1 Novel muscle growth regulator |
| 08/23/2006 | EP1692143A1 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease |
| 08/23/2006 | EP1692141A1 Substituted 3-amino-thieno¬2,3-b| pyridine-2-carboxylic acid amide compounds as ikk inhibitors |
| 08/23/2006 | EP1692140A1 Compositions useful as inhibitors of protein kinases |
| 08/23/2006 | EP1692136A2 Azepinoindole derivatives as pharmaceutical agents |
| 08/23/2006 | EP1692133A1 Diazabicyclononene derivatives and their use as renin inhibitors |
| 08/23/2006 | EP1692132A2 Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain |
| 08/23/2006 | EP1692131A2 Methods and compositions for slowing aging |
| 08/23/2006 | EP1692130A2 Phenanthridinium derivatives as dna binding agents |
| 08/23/2006 | EP1692129A1 Keto lactam compounds and use thereof |
| 08/23/2006 | EP1692128A1 Indazole compounds and methods of use thereof as protein kinase inhibitors |
| 08/23/2006 | EP1692127A2 Triphenylethylene compounds as selective estrogen receptor modulators |
| 08/23/2006 | EP1692125A2 Irciniastatins a and b |
| 08/23/2006 | EP1692123A1 Phenyl-furan compounds as vitamin d receptor modulators |
| 08/23/2006 | EP1692117A1 Oxazole derivatives of tetracyclines |
| 08/23/2006 | EP1692116A1 1,2,3-triazole amide derivatives as inhibitors of cytokine production |
| 08/23/2006 | EP1692114A1 Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament |
| 08/23/2006 | EP1692113A1 Aryl imidazoles and their use as anti-cancer agents |
| 08/23/2006 | EP1692112A1 Compounds, compositions, and methods |
| 08/23/2006 | EP1692111A2 Quinolines useful in treating cardiovascular disease |
| 08/23/2006 | EP1692110A1 Diacylhydrazine derivatives |
| 08/23/2006 | EP1692109A2 Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| 08/23/2006 | EP1692104A1 Methods of preparing compounds useful as protease inhibitors |
| 08/23/2006 | EP1692101A1 Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof |
| 08/23/2006 | EP1692099A1 Somatostatine receptor subtype 1 (sstr1) active compounds and their use in therapy |
| 08/23/2006 | EP1692097A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods |
| 08/23/2006 | EP1692096A1 Hydroxylamine derivatives |
| 08/23/2006 | EP1692095A1 Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors |
| 08/23/2006 | EP1692085A2 Inhibition of fgfr3 and treatment of multiple myeloma |
| 08/23/2006 | EP1691926A1 Phosphatase inhibitor sample collection system |
| 08/23/2006 | EP1691892A2 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 08/23/2006 | EP1691891A2 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| 08/23/2006 | EP1691842A1 Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent |
| 08/23/2006 | EP1691841A2 Compositions comprising two different populations of polymer-active agent conjugates |
| 08/23/2006 | EP1691834A2 Combination therapy |
| 08/23/2006 | EP1691821A1 Methods and compositions comprising ilex |
| 08/23/2006 | EP1691819A2 Chaperone-based therapy for niemann-pick disease |
| 08/23/2006 | EP1691818A2 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof |
| 08/23/2006 | EP1691817A2 NF-kB OLIGONUCLEOTIDE DECOY MOLECULES |
| 08/23/2006 | EP1691816A2 Pharmaceutical uses of bisphosphonates |
| 08/23/2006 | EP1691815A1 Superoxide dismutase mimics for the treatment of optic nerve and retinal damage |
| 08/23/2006 | EP1691814A2 Anti-inflammatory agents |
| 08/23/2006 | EP1691813A2 Ready-for-use injectable solution of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1h-purin-6(9h)-one, sterile, stable; closed system for packing the solution, process for eliminating alkaline residuals of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1h-purin-6(9h)-one crystals; pharmaceutical |
| 08/23/2006 | EP1691812A1 Gtpase inhibitors and methods of use |
| 08/23/2006 | EP1691811A1 Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 08/23/2006 | EP1691810A1 Substituted piperazines |
| 08/23/2006 | EP1691809A1 Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
| 08/23/2006 | EP1691808A1 Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative |
| 08/23/2006 | EP1691807A1 Indole derivatives for the treatment of bone diseases |
| 08/23/2006 | EP1691806A2 Novel therapeutic method and compositions |
| 08/23/2006 | EP1691805A1 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person |
| 08/23/2006 | EP1691804A1 Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive drugs |
| 08/23/2006 | EP1691803A1 N-alkyl pyrroles as hmg-coa reductase inhibitors |
| 08/23/2006 | EP1691802A1 Methods for the amelioration of environmental oxidant stress and the regulation of beneficial genes |
| 08/23/2006 | EP1691801A2 Synergistic anti-cancer compositions |
| 08/23/2006 | EP1691800A1 Methods and agents for inhibiting dynamin-dependent endocytosis |
| 08/23/2006 | EP1691799A2 Lipid rafts and clostridial toxins |
| 08/23/2006 | EP1691798A1 Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |
| 08/23/2006 | EP1691797A2 Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method |
| 08/23/2006 | EP1691796A1 Terrein compound having melanin biosynthesis inhibitors and its preparation |
| 08/23/2006 | EP1691795A2 Pharmaceutical compositions comprising danazol |
| 08/23/2006 | EP1691790A1 Sustained release torsemide dosage forms |
| 08/23/2006 | EP1691789A2 Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| 08/23/2006 | EP1691788A2 Phosphodiesterase v inhibitor formulations |
| 08/23/2006 | EP1691787A1 Method for making pharmaceutical multiparticulates |
| 08/23/2006 | EP1691785A1 Excipients in drug delivery vehicles |
| 08/23/2006 | EP1691783A1 Pre-metered dry powder inhaler for moisture-sensitive medicaments |
| 08/23/2006 | EP1691782A1 Medical product containing tiotropium |
| 08/23/2006 | EP1691781A1 Inhalable tiotropium and container therefor |
| 08/23/2006 | EP1691779A2 Treatment of a condition in a mammal with administration of compounds and methods of use thereof |